Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 10/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | QDPR | P09417 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20093001 | 0.93 | TYK2 (0.38) | HDAC1HDAC2HDAC3TYK2L3MBTL1 | |
| SCHEMBL20092137 | 0.89 | TYK2 (0.41) | TYK2 | |
| SCHEMBL2112353 | 0.89 | QDPR (0.49) | SIGMAR1QDPR | |
| Hydrochloric Acid SCHEMBL4435866 | 0.88 | QDPR (0.47) | SIGMAR1QDPR | |
| SCHEMBL25289702 | 0.83 | HDAC1 (0.36) | HDAC1HDAC2HDAC3TYK2WDR5 | |
| SCHEMBL20092461 | 0.83 | TYK2 (0.43) | TYK2 | |
| SCHEMBL14454641 | 0.82 | HDAC1 (0.42) | HDAC1HDAC2HDAC3WDR5QDPR | |
| SCHEMBL30490281 | 0.81 | HDAC1 (0.40) | HDAC1HDAC2HDAC3TYK2L3MBTL1 | |
| SCHEMBL20093169 | 0.81 | TYK2 (0.44) | TYK2 | |
| SCHEMBL20092390 | 0.81 | TYK2 (0.44) | TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| WO-2018075937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.